Clinical trial
Docetaxel, Cisplatin, and Amifostine in Treating Patients With Advanced…
NCT00004264 · University of Wisconsin, Madison, Other · Unknown status
Key facts
| NCT number | NCT00004264 |
|---|---|
| Title | Docetaxel, Cisplatin, and Amifostine in Treating Patients With Advanced Non-small Cell Lung Cancer |
| Official title | Phase I/II Trial of Amifostine, High-Dose Cisplatin and Docetaxel in Patients With Advanced Lung Cancer |
| Lead sponsor | University of Wisconsin, Madison, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Drug/Agent Toxicity by Tissue/Organ, Lung Cancer |
| Intervention type | Drug |
| Interventions | amifostine trihydrate, cisplatin, docetaxel |
| Start date | Jul 1, 1997 |
| First posted | Jul 26, 2004 |
| Last update posted | Dec 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: